GlassScriptPhysician profile
William J Bommer
NPI 1326029794
$194,060.18
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142K · 2020: $8,947 · 2021: $11K · 2022: $26K · 2023: $6,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,645 · Consulting Fee: $2,025 · Food and Beverage: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,645.00 |
| Consulting Fee | $2,025.00 |
| Food and Beverage | $369.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $56,519.84 | 2019-2022 | |
| Lilly USA, LLC | $46,822.07 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $41,450.24 | 2019-2023 | Eliquis, Camzyos |
| Pfizer INC. | $26,008.25 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18,863.95 | 2019 | |
| Sanofi-Aventis U.S. LLC | $3,709.26 | 2019 | |
| Biotronik INC. | $258.28 | 2019-2020 | |
| Novo Nordisk INC | $232.59 | 2019-2020 | |
| Shockwave Medical, INC | $139.74 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $24.64 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $17.43 | 2019 | |
| Amgen INC. | $13.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bommer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.